Targeted immunotherapies have become part of ATC treatment over the last decade or so, boosting recognition of tumor cells and activation of the immune system. But the studies on their effects have been fairly scarce and heterogeneous.
Targeted immunotherapies have become part of ATC treatment over the last decade or so, boosting recognition of tumor cells and activation of the immune system. But the studies on their effects have been fairly scarce and heterogeneous.